The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Leukemia P388

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Leukemia P388


High impact information on Leukemia P388

  • The active compounds isolated from the tunicate, didemnins A, B, and C, are depsipeptides, and didemnin B (a derivative of didemnin A) is the component active at the lowest concentration in inhibiting viral replication in vitro and P388 leukemia in vivo [6].
  • The same strategy produced no better results than giving either MTX or TMTX alone to (C57BL/6 x DBA/2)F1 mice bearing murine leukemia P388 cells [7].
  • Four main patterns were evident: a transport-related multidrug-resistance pattern (three sublines), a pattern similar to that for a murine P388 leukemia subline resistant to amsacrine, and two patterns not observed previously [8].
  • Because the development of resistance to cancer chemotherapeutic agents represents a major limitation of cancer chemotherapy, we investigated the mechanism of resistance by murine P388 leukemia to camptothecin (topoisomerase I inhibitor) or amsacrine (topoisomerase II inhibitor) [9].
  • Cisplatin and melphalan given ip exert a synergistic therapeutic effect against ascitic P388 leukemia in mice and have different dose-limiting toxic effects as well as favorable pharmacokinetic characteristics in ip phase I studies [10].

Chemical compound and disease context of Leukemia P388


Biological context of Leukemia P388


Anatomical context of Leukemia P388

  • Cloned lines of Adriamycin (ADR)-sensitive and -resistant P388 leukemia have been established, including P388/ADR/3 and P388/ADR/7 that are 5- and 10-fold more resistant than the cloned sensitive cell line P388/4 (Cancer Res., 46: 2978, 1986) [17].
  • P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells [21].
  • MS-209 at 1-10 microM completely reversed resistance against vincristine (VCR) in vitro in multidrug-resistant variants of mouse leukemia P388 cells (VCR-resistant P388/VCR and Adriamycin (ADM)-resistant P388/ADM) and human leukemia K562 cells (VCR-resistant K562/VCR and ADM-resistant K562/ADM) [22].
  • Proton NMR longitudinal relaxation times (T1; 10.7 MHz; 37 degrees C) were measured in the kidneys and blood serum of mice inoculated with P388 leukemia, and/or treated with the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-Pt) [23].
  • The anti-cancer drug aclarubicin (2.0 mg/kg body weight) was injected into the left popliteal lymph node (the primary draining node of the foot-pad region) or into the tail vein, 8 days after a subcutaneous inoculation of 5 x 10(5) P388 leukemia cells/mouse in the left hind paw foot-pad of mouse (donor) [24].

Gene context of Leukemia P388

  • Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells [25].
  • Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide [26].
  • The sensitivity of camptothecin-resistant mouse leukemia P388/ CPT45 cells, which fail to express detectable top1, was similar to the sensitivity of wild-type P388 cells, suggesting that top1 is not a critical target for the antiproliferative activity of Et743 [27].
  • Following the parenteral administration of tiazofurin, 2-beta D-ribofuranosylthiazole-4-carboxamide (thiazole nucleoside, TR), a potent but reversible inhibitor of IMP dehydrogenase is generated in subcutaneous nodules of the P388 leukemia [28].
  • In ascitic P388 leukemia the antineoplastic activity of CDDP given ip was not reduced significantly [29].

Analytical, diagnostic and therapeutic context of Leukemia P388


  1. Comparative genotoxicity of adriamycin and menogarol, two anthracycline antitumor agents. Bhuyan, B.K., Zimmer, D.M., Mazurek, J.H., Trzos, R.J., Harbach, P.R., Shu, V.S., Johnson, M.A. Cancer Res. (1983) [Pubmed]
  2. Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. Barbieri, B., Giuliani, F.C., Bordoni, T., Casazza, A.M., Geroni, C., Bellini, O., Suarato, A., Gioia, B., Penco, S., Arcamone, F. Cancer Res. (1987) [Pubmed]
  3. Chemoimmunotherapy of B 16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones. Li, L.H., Johnson, M.A., Moeller, R.B., Wallace, T.L. Cancer Res. (1984) [Pubmed]
  4. Antitumor effect of a new multienzyme inhibitor of polyamine synthetic pathway, methylglyoxal-bis(cyclopentylamidinohydrazone), against human and mouse leukemia cells. Hibasami, H., Maekawa, S., Murata, T., Nakashima, K. Cancer Res. (1989) [Pubmed]
  5. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Tsuruo, T., Iida, H., Nojiri, M., Tsukagoshi, S., Sakurai, Y. Cancer Res. (1983) [Pubmed]
  6. Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate. Rinehart, K.L., Gloer, J.B., Hughes, R.G., Renis, H.E., McGovren, J.P., Swynenberg, E.B., Stringfellow, D.A., Kuentzel, S.L., Li, L.H. Science (1981) [Pubmed]
  7. Rapid development of resistance to antifolates in vitro: possible clinical implication. Sobrero, A., Aschele, C., Rosso, R., Nicolin, A., Bertino, J.R. J. Natl. Cancer Inst. (1991) [Pubmed]
  8. Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. Finlay, G.J., Baguley, B.C., Snow, K., Judd, W. J. Natl. Cancer Inst. (1990) [Pubmed]
  9. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. Tan, K.B., Mattern, M.R., Eng, W.K., McCabe, F.L., Johnson, R.K. J. Natl. Cancer Inst. (1989) [Pubmed]
  10. Intraperitoneal chemotherapy with cisplatin and melphalan. Piccart, M.J., Abrams, J., Dodion, P.F., Crespeigne, N., Sculier, J.P., Pector, J.C., Finet, C., Nouwijnck, C., Bondue, H., Atassi, G. J. Natl. Cancer Inst. (1988) [Pubmed]
  11. Biochemical parameters of resistance of an adriamycin-resistant subline of P388 leukemia to emetine, an inhibitor of protein synthesis. Chitnis, M.P., Johnson, R.K. J. Natl. Cancer Inst. (1978) [Pubmed]
  12. Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D. Wilkoff, L.J., Dulmadge, E.A. J. Natl. Cancer Inst. (1978) [Pubmed]
  13. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. Doroshow, J.H., Locker, G.Y., Ifrim, I., Myers, C.E. J. Clin. Invest. (1981) [Pubmed]
  14. Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Ardalan, B., Cooney, D.A., Jayaram, H.N., Carrico, C.K., Glazer, R.I., Macdonald, J., Schein, P.S. Cancer Res. (1980) [Pubmed]
  15. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta. Borden, E.C., Sidky, Y.A., Hatcher, J.F., Bryan, G.T. Cancer Res. (1988) [Pubmed]
  16. Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells. Capranico, G., De Isabella, P., Penco, S., Tinelli, S., Zunino, F. Cancer Res. (1989) [Pubmed]
  17. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Deffie, A.M., Alam, T., Seneviratne, C., Beenken, S.W., Batra, J.K., Shea, T.C., Henner, W.D., Goldenberg, G.J. Cancer Res. (1988) [Pubmed]
  18. Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. Lee, H.H., Palmer, B.D., Boyd, M., Baguley, B.C., Denny, W.A. J. Med. Chem. (1992) [Pubmed]
  19. Rapid kinetics of the interaction between daunomycin and drug-sensitive or drug-resistant P388 leukemia cells. Soto, F., Canaves, J.M., Gonzalez-Ros, J.M., Ferragut, J.A. FEBS Lett. (1992) [Pubmed]
  20. Intracellular glutathione depletion and reactive oxygen species generation are important in alpha-hederin-induced apoptosis of P388 cells. Swamy, S.M., Huat, B.T. Mol. Cell. Biochem. (2003) [Pubmed]
  21. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells. Radel, S., Fredericks, W., Mayhew, E., Baker, R. Cancer Chemother. Pharmacol. (1990) [Pubmed]
  22. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Sato, W., Fukazawa, N., Nakanishi, O., Baba, M., Suzuki, T., Yano, O., Naito, M., Tsuruo, T. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  23. The relationship between serum water proton T1 and protein content in the P388 leukemic mouse and the effect of chemotherapy by cis-diamminedichloroplatinum(II). Raeymaekers, H.H., Callens, F., Eisendrath, H., Atassi, G., Fossoul, C., Vandewalle, J., Gielen, M., Willem, R. NMR in biomedicine. (1988) [Pubmed]
  24. Enhanced anti-cancer effects of intralymphatic aclarubicin on distal lymph node metastases: quantitative evaluation using a new experimental model in mice. Hagiwara, A., Takahashi, T., Sawai, K., Seiki, K., Ito, M., Sakakura, C., Shobayashi, S. Anticancer Drugs (1991) [Pubmed]
  25. Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Wang, F.P., Wang, L., Yang, J.S., Nomura, M., Miyamoto, K. Biol. Pharm. Bull. (2005) [Pubmed]
  26. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide. Nakashima, E., Matsushita, R., Negishi, H., Nomura, M., Harada, S., Yamamoto, H., Miyamoto, K., Ichimura, F. Journal of pharmaceutical sciences. (1995) [Pubmed]
  27. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Takebayashi, Y., Goldwasser, F., Urasaki, Y., Kohlhagen, G., Pommier, Y. Clin. Cancer Res. (2001) [Pubmed]
  28. Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity. Cooney, D.A., Jayaram, H.N., Glazer, R.I., Kelley, J.A., Marquez, V.E., Gebeyehu, G., Van Cott, A.C., Zwelling, L.A., Johns, D.G. Adv. Enzyme Regul. (1983) [Pubmed]
  29. Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle. Aamdal, S., Fodstad, O., Kaalhus, O., Pihl, A. J. Natl. Cancer Inst. (1984) [Pubmed]
  30. Intracellular adriamycin levels and cytotoxicity in adriamycin-sensitive and adriamycin-resistant P388 mouse leukemia cells. Ganapathi, R., Reiter, W., Krishan, A. J. Natl. Cancer Inst. (1982) [Pubmed]
  31. Reversal of anticancer multidrug resistance by the ardeemins. Chou, T.C., Depew, K.M., Zheng, Y.H., Safer, M.L., Chan, D., Helfrich, B., Zatorska, D., Zatorski, A., Bornmann, W., Danishefsky, S.J. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  32. Cross-linkage of nucleophosmin in tumor cells by nitrogen mustard. Chan, P.K. Cancer Res. (1989) [Pubmed]
  33. Enhanced levels of cyclic AMP, adenosine(5')tetraphospho(5')adenosine and nucleoside 5'-triphosphates in mouse leukemia P388/D1 after treatment with cis-diamminedichloroplatinum(II). Just, G., Holler, E. Biochem. Pharmacol. (1991) [Pubmed]
WikiGenes - Universities